Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) (NCT06602453).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 7:52 PM
Resolution Evidence
Outcome
NO
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Public readout points negative for this exact Phase 2 trial: Genentech said interim data suggested GDC-8264 was unlikely to show significant clinical benefit, and reporting tied that directly to failure to reach the primary efficacy endpoint. ClinicalTrials.gov also shows the study terminated with no results posted.

Sources
Web Searchfiercebiotech.com3/19/26
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure

Fierce reports Genentech stopped this Phase 2 study after interim data indicated it was unlikely to demonstrate significant clinical benefit; the primary efficacy endpoint was not expected to be delivered.

View source
ClinicalTrialsclinicaltrials.gov1/6/26
Study Details | NCT06602453 | ClinicalTrials.gov

ClinicalTrials.gov lists NCT06602453 and notes 'No Results Posted'; the study record reflects termination rather than a completed positive readout.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NOAccepted95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Public readout points negative for this exact Phase 2 trial: Genentech said interim data suggested GDC-8264 was unlikely to show significant clinical benefit, and reporting tied that directly to failure to reach the primary efficacy endpoint. ClinicalTrials.gov also shows the study terminated with no results posted.

Found Apr 1, 2026, 7:52 PMOutcome date Mar 19, 2026, 12:00 AMReviewed Apr 1, 2026, 7:56 PM
Web Searchfiercebiotech.comMar 19, 2026, 12:00 AM
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure
Fierce reports Genentech stopped this Phase 2 study after interim data indicated it was unlikely to demonstrate significant clinical benefit; the primary efficacy endpoint was not expected to be delivered.
ClinicalTrialsclinicaltrials.govJan 6, 2026, 12:00 AM
Study Details | NCT06602453 | ClinicalTrials.gov
ClinicalTrials.gov lists NCT06602453 and notes 'No Results Posted'; the study record reflects termination rather than a completed positive readout.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:56 PM

Will the results be positive?

PendingtoNOcurrentNO
GPT-5.4 (OpenAI)95% confidenceReviewed Apr 1, 2026, 7:56 PM

Public readout points negative for this exact Phase 2 trial: Genentech said interim data suggested GDC-8264 was unlikely to show significant clinical benefit, and reporting tied that directly to failure to reach the primary efficacy endpoint. ClinicalTrials.gov also shows the study terminated with no results posted.